Model-Informed Drug Development

2021 Virtual Conference

Working with Cognigen Kevin Dykstra, PhD FCP Vice President, Consulting Services




Drug Development Success is Measured in the Big Picture

Lead Pharmacology Selection **Regulatory Success** Efficiency ADMET DMPK **Patient Benefit** Outcomes **Commercial Success** Clinical Efficacy



At Simulations Plus We Put It All Together



We have the Solutions and the People to Address Your Drug Development Questions!

What it is Like to Work With Us?

We believe the relationships we build with our clients are critical and a highly interactive collaboration not only allows us to deliver results as quickly as possible, but also ensures a higher quality deliverable

- Regular interactions ensure the relevancy of results as the knowledge-base continues to evolve
- Transparency provided by progress updates eliminates surprises
- Synergies come from a shared knowledge-base of expertise and experience
- We welcome involvement, participation, and input from stakeholders outside of M&S


We have the experience and capacity to meet your development needs on time

- Currently over 50 scientists and technologists and growing!
- Experience in most therapeutic areas and all phases of drug development
 - Oncology: tumor size, cell counts, OR, PFS, OS
 - Psychiatry and other CNS diseases: disease progress model, characterization of placebo response, E-R efficacy and safety models for categorical endpoints
 - Small molecules, mAb, biologics, ADCs, liposomes
 - Concentration-QT models and risk assessment

- Anti-virals/anti-infectives: Viral load, MIC, disease burden, TA analyses
- Diabetes and obesity: PK/PD models of efficacy and safety endpoints
- Pediatrics: PIP development, dose selection based on exposure-matching, adjustments by age, weight
- Well-established quality management system and successful client audit record

We have the Systems Infrastructure to ensure data integrity and secure access

- Fully validated, private "cloud" computing to address computational requirements in regulated industries
- Redundant enterprise-grade storage




- Uninterruptable power supply protects entire datacenter
- Comprehensive off-site backup facilities
- Diesel generator provides long-term backup power
- Continuous system-wide environmental monitoring

THANK YOU We look forward to collaborating!





Model-Informed Drug Development



Questions & Answers

Learn More! www.simulations-plus.com

SI SimulationsPlus Cognigen | DILIsym Services | Lixoft Model-Informed Drug Development

2021 Virtual Conference Partner With Us...

John DiBella

President, Simulations Plus Division

Kevin Dykstra

Vice President, Consulting Services

Brett Howell

President, DILIsym Services Division

SI Simulations Plus Cognigen | DILIsym Services | Lixoft




2021 Virtual Conference

Cognigen | DILIsym Services | Lixoft

The Vision:

Saying "I do" to the Machine Learning / PBBM-PK / QST(P) / Pharmacometrics marriage...



>10% in total revenues invested in software R&D in 2020 (additional funding from collaboration partners)

lodelInformed Drug Development.

St SimulationsPlus

Cognigen | DILIsym Services | Lixoft

Clients Driving Software R&D: Active Funded Collaborations

FDA: Ocular model extensions

Large Pharma: Pulmonary model extensions

5-

Large Pharma: ACAT[™] model enhancements

Cosmetics Europe: Dermal model extensions

FDA: Dermal product quality attributes

FDA: Oral cavity model extensions

Large Pharma: Virtual BE Trial Simulator

Other Software

RENAsym[™]: Drug-induced kidney injury QST

IPFsym[™]: Pulmonary fibrosis QSP

ADMET Predictor®: HT-PBPK simulations

PKPlus[™]: HT-PK data analysis



Model-Informed Drug Development

Software R&D Collaborations: Roles and Responsibilities

Sponsor provides:

- 1. Scientific guidance based on subject knowledge
- 2. Selected internal data to validate proposed modifications
- 3. Feedback on implementation (e.g., GUI design, workflows, deployment within sponsor's IT system)
- 4. Funding of FTE(s) to prioritize and accelerate development
- 5. Assistance with the preparation of draft manuscripts for publication

Simulations Plus provides:

- 1. Project management
- 2. Scientific expertise building mathematical models
- 3. Algorithmic and logic code updates into the simulation engine
- 4. Beta versions of the software for testing
- 5. Pre-built compound models for future internal use by sponsor
- 6. Assistance with the preparation of draft manuscripts for publication





Software R&D Collaborations: We Are All Winners!

WINNER! Sponsor receives:

- 1. Customized functionality within commercially qualified/maintained software
- 2. Validated compound models developed using sponsor data
- 3. Free licenses to new features
- 4. Publications describing the modeling methodology and validation
- 5. Recognition from industry/regulatory agencies for advancing the utility of modeling & simulation

WINNER! Simulations Plus receives:

- 1. Data, funding and scientific expertise to support model development
- 2. Ability to distribute new functionality to other clients (IMPORTANT: no data is ever shared!)
- 3. Presentations and publications describing the modeling methodology and validation

WINNER! Regulatory agencies and industry receive:

1. Access to innovative, validated science to develop safe, effective medicines more efficiently





Model-Informed Drug Development

2021 Virtual Conference

Collaborating With Us – Consortium Membership

Brett Howell, President of DILIsym Services Division



Summary

- QST model development is more effective within a consortium style setting
 - Collaboration
 - Sharing
 - Common deliverables
- DILIsym and RENAsym are developed within consortia
 - Partner with us today via membership!
- Licensing, consulting, and training options are available outside of membership as well





Our <u>*QSP/QST*</u> Solutions Employ Comprehensive, Mechanistic Models to Address Key Drug Development Areas


DILISYM™ RENAsym® NAFLDsym® IPFsym™ RADAsym™

Services

Model-Informed Drug Development

2021 Virtual Conf

QSP Consulting QST Consulting



QSP/QST



The DILI-sim Initiative is a Partnership Between DILIsym Services and Pharmaceutical Companies to Minimize DILI





Model-Informed Drug Development



Select Sample of Current Companies Licensing DILIsym

For a comprehensive review of progress, see Watkins 2019: Clin Transl Sci


<u>Overall Goals</u>

- Improve patient safety
- Reduce the need for animal testing
- Reduce the costs and time necessary to develop new drugs

History

- Officially started in 2011
- 20 major pharmaceutical companies have participated
- Members have provided compounds, data, and conducted experiments to support effort
- Over \$10 million total invested in project
- <u>At least 29 cases of use for regulatory purposes</u>
- **Over 30 publications**





DILI-sim Membership Benefits: Safety Strategy and Regulatory Guidance Updates in Real Time

- Representatives from member companies can attend quarterly DILI-sim and RENAsym update meetings with a *front* row seat to:
 - Regulatory case studies and examples in real-time (prior to publication) related to DILIsym and RENAsym applications
 - Updates on regulatory feedback and guidance development related to QST and DILIsym/RENAsym
 - New scientific updates in the general areas of liver and kidney injury
 - Monitor progress and provide feedback, along with model design review sessions
- Attendance, voting, and data generation are optional benefits of membership and are not required

Benefit: influence over DILIsym development

- Member companies guide DILIsym development
- DILI-sim members have option to donate data from current or failed compounds to serve as exemplars for DILIsym

DILI-sim membership terms

Tier 1 (3 year contract) members - contracts on a rolling basis (e.g. starting July 1st ends June 30, three years later) *License agreements can also be utilized to obtain access to DILIsym instead of membership



DILI-sim Initiative

Consortium Distributing and Developing Software for Predicting and Preventing Drug-Induced Liver Injury (DILI)

Join Today and Support Cutting Edge Research to Make Patients Safer!

Benefits of Stage 4 DILI-sim Membership

- Two global, floating end-user licenses to the current version of the DILIsym® software package
- Includes integrated GastroPlus® version, when available
- Licenses to an add-on feature of DILIsym that enables use of server/cloud parallel computing with unlimited nodes (upcharge for non-members)
- · 31% discount on consulting services related to DILIsym
- 10 total hours of private training for employees of the Member company related to DILIsym use
- The right to vote on DILIsym software development items going forward
- Attendance at DILI-sim research, development, and software update meetings/discussions (typically held quarterly)
- Access to the DILIsym Discovery Support Program (DDSP), a Members-only, lower cost program for enabling internal software use




Now includes **RENAsym[™] Consortium** membership at no additional cost!



DILISYM Services



Dr. Paul B. Watkins Director, DILI-sim Initiative; Chair, Scientific Advisory Board



ationsPlus mServices | Lixoft

RENAsym Scientific Advisory Board



Dr. Paul B. Watkins Director, Institute for Drug Safety Sciences Howard Q. Ferguson Distinguished Professor Of Medicine UNC Eshelman School of Pharmacy



Dr. K Melissa Hallow Assistant Professor School of Chemical, Materials, and Biomedical Engineering University of Georgia



Lauren Aleksunes, PharmD, PhD, DABT Associate Professor, Graduate Director Pharmacology and Toxicology Rutgers University

Model-Informed Drug Development

2021 Virtual Conference



Dr. Frank Sistare Former Executive Director of the Department of Laboratory Sciences and Investigative Toxicology within Safety Assessment at Merck Former Co-Chair, Nephrotoxicity Working Group, PSTC Formerly also with FDA/CDER for 15 years



Dr. Zheng Dong Leon H. Charbonnier Endowed Chair, Regents Professor Medical College of Georgia Senior Career Scientist, Director of Research Charlie Norwood VA Medical Center



Dr. Ravinder L Mehta Professor of Medicine in the Division of Nephrology and Associate Chair for Clinical Affairs Department of Medicine University of California, San Diego (UCSD)

go (UCSD) JationsPlus Cognigen | DILIsym Services | Lixoft

Areas of Focus for RENAsym

- **Context of Use**: define critical needs from in silico platform to support various aspects of drug development
- **Oversight:** review progress on RENAsym development and provide feedback and guidance to ensure optimal usefulness
- **Data Inputs:** collaboratively assess in vitro platforms as useful inputs into RENAsym and provide input on new study designs
- **Share:** share data, and eventually RENAsym use insight and feedback, with other members
- *Visibility*: use consortium as a platform to advance the case for human predictions from in vitro systems + simulations; also provides vehicle for engagement with regulators on use of tool





Other Partnership Avenues

QSP Platform License Provides Opportunity to Actively Utilize QSP Model

Annual licenses to NAFLDsym, IPFsym, and other QSP platforms are available


- Includes capabilities of predicting effects of treatments on numerous disease aspects
- Includes 10 hours of training per product
- Local desktop installations only
- No network shareable licenses
- Must be renewed annually
- Additional licenses can be made available at reduced, volume pricing
- Equations can be viewed by users
 - Can be modified to represent novel targets
 - No original NAFLDsym v2A code can be ported out to other MATLAB files or languages without the permission of DILIsym Services

sults View Help			File Results View Hel	P	
				9	
ingle Setup			SimSingle Setup		
New SimSingle	NAFLD Pt 1 Lipolysis 24hr		New SimSingle	IPF_Simulated_Pt_1_1year	
Load SimSingle			Load SimSingle		F. E
Parameters			Input Parameters		
		Linolysis v v Customize	Species	Parameters_Species_Human_Simulate	d Pt 1 v v Customize
Species	Parameters_Species_NAFLD_1_TG		Drug	Parameters_Drug_Blank_v0A	 Customize
Drug	Parameters_Drug_Human_Mitochor			- arameters_brog_blank_tox	Mechanism
		Mechanism			
Caloric Intake	Parameters_Calories_Human_v1F_v	/12 v Customize	Caloric Intake	Parameters_Calories_Blank_v0A	 Customize
Comp W Dosing	No parameter sets available	 Customize 			
Comp X Dosing	💰 NAFLDsym Parameter Customi	zation		– 🗆 X	
Comp Y Dosing	Group	Subgroup	Variable	Value	
	All Groups ~		Parameter Not Selected ~	+	Customize
Time	All Groups	All Subgroups	marameter Not Selected		 Customize
Solver	Species	Biological specifications	Body Mass 10	12.4398 kg	
Input Panel					~ Viewer
	Species	Basal levels	Basal fasting glucose 6	.6157 mmol/L X	Param Sweep Data Comparison
Simulate	Species	Basal levels	Basal liver triglycerides 97	7.2771 mmol/L X	Optimization
Specify Data	Species	Basal levels	Basal plasma triglycerides	.6893 mmol/L X	
Plot	opecies	Dasai levels	concentration	.0093	Save Results SimSingle
	Spec	5			×
	Spec	Group	Subgroup	Output Variable	
		Clinical Measure		All Variables V	
	Spec				
	Spec	2.6e+02			
	Blank Panel	~			
	Plasma ALT	^			
		2.1e+02 -			
		S Mar			
		(TUI) LTP Euseel Bassa		SimPops individual 2	Places ALT (10)
		E 1.56 Oz			asing Act (O/c/)
		a hour			
		94 - 4			
		h			
		· hour			
		37	1.5e+03 3e+03 4.5e+03	6e+03	
	Remove	Save	Time (hours)		
	Standard	~ Log (X)	Log (Y) Add Data	Show Individuals	
			C 101		
	Time	✓ Table View	Export Plot eDISH	Reset	






General Project Timeline and <u>Deliverables</u>






Model-Informed Drug Development



Questions & Answers

Learn More! www.simulations-plus.com

SI SimulationsPlus Cognigen | DILIsym Services | Lixoft



DILI-sim Membership Benefits: Safety Strategy and Regulatory Guidance Updates in Real Time

- Representatives from member companies can attend quarterly DILI-sim and RENAsym update meetings with a *front* row seat to:
 - Regulatory case studies and examples in real-time (prior to publication) related to DILIsym and RENAsym applications
 - Updates on regulatory feedback and guidance development related to QST and DILIsym/RENAsym
 - New scientific updates in the general areas of liver and kidney injury
 - Monitor progress and provide feedback, along with model design review sessions
- Attendance, voting, and data generation are optional benefits of membership and are not required

Benefit: influence over DILIsym development

- Member companies guide DILIsym development
- DILI-sim members have option to donate data from current or failed compounds to serve as exemplars for DILIsym

DILI-sim membership terms

Tier 1 (3 year contract) members - contracts on a rolling basis (e.g. starting July 1st ends June 30, three years later)
 *License agreements can also be utilized to obtain access to DILIsym instead of membership



DILI-sim Initiative

Consortium Distributing and Developing Software for Predicting and Preventing Drug-Induced Liver Injury (DILI)

Join Today and Support Cutting Edge Research to Make Patients Safer!

Benefits of Stage 4 DILI-sim Membership

- Two global, floating end-user licenses to the current version of the DILIsym® software package
- Includes integrated GastroPlus® version, when available
- Licenses to an add-on feature of DILIsym that enables use of server/cloud parallel computing with unlimited nodes (upcharge for non-members)
- · 31% discount on consulting services related to DILIsym
- 10 total hours of private training for employees of the Member company related to DILIsym use
- The right to vote on DILIsym software development items going forward
- Attendance at DILI-sim research, development, and software update meetings/discussions (typically held quarterly)
- Access to the DILIsym Discovery Support Program (DDSP), a Members-only, lower cost program for enabling internal software use



Now includes **RENAsym[™] Consortium** membership at no additional cost!



DILISYM Services



Dr. Paul B. Watkins Director, DILI-sim Initiative; Chair, Scientific Advisory Board



ationsPlus ym Services | Lixoft

RENAsym Scientific Advisory Board



Dr. Paul B. Watkins Director, Institute for Drug Safety Sciences Howard Q. Ferguson Distinguished Professor Of Medicine UNC Eshelman School of Pharmacy



Dr. K Melissa Hallow Assistant Professor School of Chemical, Materials, and Biomedical Engineering University of Georgia



Lauren Aleksunes, PharmD, PhD, DABT Associate Professor, Graduate Director Pharmacology and Toxicology Rutgers University

Model-Informed Drug Development


2021 Virtual Conference




Dr. Frank Sistare Former Executive Director of the Department of Laboratory Sciences and Investigative Toxicology within Safety Assessment at Merck Former Co-Chair, Nephrotoxicity Working Group, PSTC Formerly also with FDA/CDER for 15 years



Dr. Zheng Dong Leon H. Charbonnier Endowed Chair, Regents Professor Medical College of Georgia Senior Career Scientist, Director of Research Charlie Norwood VA Medical Center



Dr. Ravinder L Mehta Professor of Medicine in the Division of Nephrology and Associate Chair for Clinical Affairs Department of Medicine University of California, San Diego (UCSD)



Cognigen | DILIsym Services | Lixoft

Areas of Focus for RENAsym

- **Context of Use**: define critical needs from in silico platform to support various aspects of drug development
- **Oversight:** review progress on RENAsym development and provide feedback and guidance to ensure optimal usefulness
- **Data Inputs:** collaboratively assess in vitro platforms as useful inputs into RENAsym and provide input on new study designs
- **Share:** share data, and eventually RENAsym use insight and feedback, with other members
- *Visibility*: use consortium as a platform to advance the case for human predictions from in vitro systems + simulations; also provides vehicle for engagement with regulators on use of tool





Other Partnership Avenues

QSP Platform License Provides Opportunity to Actively Utilize QSP Model

Annual licenses to NAFLDsym, IPFsym, and other QSP platforms are available


- Includes capabilities of predicting effects of treatments on numerous disease aspects
- Includes 10 hours of training per product
- Local desktop installations only
- No network shareable licenses
- Must be renewed annually
- Additional licenses can be made available at reduced, volume pricing
- Equations can be viewed by users
 - Can be modified to represent novel targets
 - No original NAFLDsym v2A code can be ported out to other MATLAB files or languages without the permission of DILIsym Services

sults View Help			File Results View	Help		
÷e≩e≩e≩⊙				09		
ingle Setup New SimSingle Load SimSingle	NAFLD_Pt_1_Lipolysis_24hr		SimSingle Setup New SimSing Load SimSing	gle IPF_Simulated_Pt_1_	1year	6
Parameters		Lipplysis y Customize	Input Parameters Species		Human_Simulated_Pt_1_v v	Customize
Species Drug	Parameters_Species_NAFLD_1_TG Parameters_Drug_Human_Mitochon		Drug	Parameters_Drug_Bla	nk_v0A v	Customize Mechanism
Caloric Intake Comp W Dosing Comp X Dosing	Parameters_Calories_Human_v1F_v No narameter sets available NAFLDsym Parameter Customic	~ Customize	Caloric Intake	Parameters_Calories	Blank_v0A v	Customize
Comp Y Dosing Time Solver	Group All Groups ~	Subgroup All Subgroups	Variable Parameter Not Selected V	Value	+ × ×	Customize Customize
Input Panel	Species Species	Biological specifications Basal levels	Body Mass Basal fasting glucose	102.4398 kg 6.6157 mmol/L	X Param Sweep	Viewer Data Comparison
Simulate Specify Data Plot	Species Species	Basal levels Basal levels	Basal liver triglycerides Basal plasma triglycerides concentration	97.2771 mmol/L 1.6893 mmol/L	Coptimization	SimSingle
	Spec Spec Spec Spec Blank Panel Blank Panel Bl	Cince Measures Cince Measures 2.6+02 (10) 1/19 units 1.5+02 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	Subgroup ✓ Clinical Chemistry S (5+03 10+00) 1.5+03 10+000 1.5+03 4.6000 1.5+03 4.6000 1.5+03 4.6000 1.5+03 10+0000 1.5+03 10+0000 1.5+0000 1.5+0000 1.5+0000 1.5+0000 1.5+00000 1.5+00000 1.5+00000 1.5+000000 1.5+000000 1.5+000000 1.5+0000000 1.5+000000000 1.5+000000000000000000000000000000000000	5 5 m P	ope individual 2 Pleane ALT (M	× .
	Time	~ Table View	Export Plot eDISH	Reset		






General Project Timeline and <u>Deliverables</u>





Model-Informed Drug Development



Questions & Answers

Learn More! www.simulations-plus.com

SI SimulationsPlus Cognigen | DILIsym Services | Lixoft